New hope for aggressive lymphoma: drug cocktail aims to control High-Risk MCL

NCT ID NCT07257055

Recruiting now Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is testing whether adding the drug glofitamab after an initial treatment with acalabrutinib (or zanubrutinib) and rituximab can better control high-risk mantle cell lymphoma (MCL) in people who have not been treated before. The study will enroll 30 participants and primarily look at safety and side effects. The goal is to find a more effective way to manage this aggressive cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Acalabrutinib (or Zanubrutinib), Rituximab, and Glofitamab
What this could lead to: If successful, this could offer a more effective treatment approach for people with high-risk mantle cell lymphoma, potentially improving disease control without needing long-term chemotherapy.
What could go wrong: This is a small, early-phase study (30 people) focused on safety and side effects. It may not lead to a lasting benefit, and the combination of drugs could cause serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BTKI are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mantle cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BTKI GLOFITAMAB MCL PHASE 2 STUDY RITUXIMAB

Contacts and locations

Locations

MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.